Tropanserin
Tropanserin (INN; MDL-72,422) is a drug which acts as a potent and selective 5-HT3 receptor antagonist.[1] It was investigated in clinical trials for the treatment of migraine in the 1980s but was never marketed.[2]
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C17H23NO2 |
Molar mass | 273.376 g·mol−1 |
3D model (JSmol) | |
| |
|
See also
References
- King FD, Jones BJ, Sanger GJ (22 October 1993). 5-Hydroxytryptamine-3 Receptor Antagonists. CRC Press. p. 244. ISBN 978-0-8493-5463-2. Retrieved 6 May 2012.
- Johnson G (1 August 1987). "Recent Advances in Migraine Research". In Bailey DM (ed.). Annual Reports in Medicinal Chemistry. 22. Academic Press. p. 44. doi:10.1016/S0065-7743(08)61153-7. ISBN 978-0-08-058366-2.
- US 4563465, Fozard JR, Gittos MW, "Treatment of migraine with substituted tropyl benzoate derivatives", issued 7 January 1986, assigned to Merrell Dow Pharma
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.